SAN LUIS OBISPO, California – June 11, 2003 – FzioMed, Inc. announced today that it has been awarded United States patent 6,566,345 covering new formulations and delivery methods for the company’s Oxiplex® technology. Oxiplex® is a unique polymer technology developed by FzioMed for use in applications such as post-surgical adhesion prevention.
The patent covers new formulations of Oxiplex® and devices for dispensing Oxiplex® foams, gels and sprays. It includes claims for the use of Oxiplex® for the delivery of drugs in the treatment of post-surgical adhesions.
“We’re moving the Oxiplex® platform technology in exciting directions with new uses, novel formulations and innovative devices,” said Richard Berg, Ph.D., Vice President of Research and Development for FzioMed. “This new patent, FzioMed’s ninth, extends the company’s proprietary reach.”
FzioMed is a privately held biomedical company engaged in the development and commercialization of advanced, absorbable biosurgery products based on the company’s patented Oxiplex® platform technology. Oxiplex® is an innovative polymer material that is formulated for a variety of surgical indications and markets. Products include those for the prevention of post-surgical adhesions, drug delivery and hemostasis. FzioMed products are at various stages of clinical and pre-clinical development, and commercialization, and are directed towards high growth markets in the rapidly growing field of biosurgery.
FzioMed® and Oxiplex® are registered trademarks of FzioMed, Inc.